Acute mitochondrial actions of glitazones on the liver: A crucial parameter for their antidiabetic properties

Cellular Physiology and Biochemistry

Volumn 28, Issue 5, 2011, Pages 899-910

  Sanz, María Nieves ^a   Sánchez Martín, Carlos ^a   Detaille, Dominique ^b   Vial, Guillaume ^b   Rigoulet, Michel ^c   El Mir, Mohammed Yehia ^a   Rodríguez Villanueva, Gloria ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Domaine Universitaire   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Direct effects; Electron transport chain complexes; Glitazones; Liver; Mitochondria; Oxidative phosphorylation; Oxygen consumption; PTP; ROS production

Indexed keywords

2,4 DINITROPHENOL; ADENOSINE DIPHOSPHATE; GLITAZONE DERIVATIVE; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING; CELL ACTIVITY; CELL ISOLATION; CONTROLLED STUDY; FLUORESCENCE; LIVER CELL; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; SPECTROMETRY;

EID: 83755183436     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000335804     Document Type: Article

References (52)

1. Barnett AH: Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vascular Health and Risk Management 2009;5:141-151.
2. Nisoli E, Cozzi V, Carruba MO: Amino acids and mitochondrial biogenesis. Am J Cardiol 2008;101:22E-25E. 3 Vial G, Dubouchaud H, Leverve XM: Liver mitochondria and insulin resistance. Acta Biochim Pol 2010;57:389-392.
3. Vial G, Dubouchaud H, Leverve XM: Liver mitochondria and insulin resistance. Acta Biochim Pol 2010;57:389-392.
4. Civitarese AE, Ravussin E: Mitochondrial energetics and insulin resistance. Endocrinology 2008;149:950-954.
5. Toledo FG, Menshikova EV, Ritov VB, Azuma K, Radikova Z, DeLany J, Kelley DE: Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes 2007;56:2142-2147. (Pubitemid 47195831)
6. Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes: Diabetes 2008;57:1446-1154.
7. Murrant CL & Reid MB: Detection of reactive oxygen and reactive nitrogen species in skeletal muscle. Microsc Res Techniq 2001;55:236-248. (Pubitemid 33136323)
8. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84. (Pubitemid 44566469)
9. Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A: Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 2009;89:27-71.
10. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M: Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009;16:94-112.
11. Crosby MB, Svenson JL, Zhang J, Nicol CJ, Gonzalez FJ, Gilkeson GS: Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. J Pharmacol Exp Ther 2005;312:69-76. (Pubitemid 40096454)
12. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C: Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key Biochem Pharmacol 2005;70:177-188. (Pubitemid 40814400)
13. Konrad D, Rudich A, Bilan PJ, Patel N, Richardson C, Witters LA, Klip A: Troglitazone causes acute mitochondrial membrane depolarisation and an AMPKmediated increase in glucose phosphorylation in muscle cells, Diabetologia 2005;48:954-966. (Pubitemid 40767990)
14. Bova MP, Tam D, McMahon G, Mattson MN: Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol Lett 2005;155:41-50. (Pubitemid 39600735)
15. Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, Pelligrino D, Galea E, Feinstein DL: Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003;278:5828-5836. (Pubitemid 36800829)
16. Pérez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, Jordán J, Ceña V, Llopis J: Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma, J Biol Chem 2004;279:8976-8985.
17. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, Furnsinn C: Thiazolidinediones, like metformin, inhibit respiratory complex I: A common mechanism contributing to their antidiabetic actions. Diabetes 2004;53:1052-1059. (Pubitemid 38436618)
18. Scatena R, Bottoni P, Martorana GE, Ferrari F, De Sole P, Rossi C, Giardina B: Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochem Biophys Res Commun 2004;319:967-973. (Pubitemid 38739414)
19. Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, Mathews WR: Identification of a novel mitochondrial protein (" mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 2004;286:E252-260. (Pubitemid 38140317)
20. Gillies PS, Dunn CJ: Pioglitazone. Drugs 2000;60:333-343.
21. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly. Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-418.
22. Berry MN, Friend DS: High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structural study. J Cell Biol 1969;43:506-520.
23. Groen AK, Sips HJ, Vervoorn RC, Tager JM: Intracellular compartmentation and control of alanine metabolism in rat liver parenchymal cells. Eur J Biochem 1982;122:87-93. (Pubitemid 12142822)
24. Klingenberg M, Slenczka W: Pyridine nucleotide in liver mitochondria. An analysis of their redox relationships. Biochem Z 1959;331:486-517.
25. Gornall AG, Vardawill CJ, David MM: Determination of serum proteins by means of the biuret reaction. J Biol Chem 1948;177:751-766.
26. Nogueira V, Rigoulet M, Piquet MA, Devin A, Fontaine E, Leverve XM: Mitochondrial respiratory chain adjustment to cellular energy demand. J Biol Chem 2001;276:46104-46110.
27. Hirst J, King MS, Pryde KR: The production of reactive oxygen species by complex I. Biochem Soc Trans 2008;36:976-980.
28. Liu Y, Fiskum G, Schubert D: Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 2002;80:780-787. (Pubitemid 34809230)
29. Dumas JF, Argaud L, Cottet-Rousselle C, Vial G, Gonzalez C, Detaille D, Leverve X, Fontaine E: Effect of transient and permanent permeability transition pore opening on NAD(P)H localization in intact cells. J Biol Chem 2009;284:15117-15125.
30. Leverve X: Hyperglycemia and oxidative stress: complex relationships with attractive prospects. Intensive Care Med 2003;29:511-514. (Pubitemid 36523661)
31. Choo HJ, Kim JH, Kwon OB, Lee CS, Mun JY, Han SS, Yoon YS, Yoon G, Choi KM, Ko YG: Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia 2006;49:784-791. (Pubitemid 43361881)
32. Ghosh S, Patel N, Rahn D, McAllister J, Sadeghi S, Horwitz G, Berry D, Wang KX, Swerdlow RH: The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol Pharmacol 2007;71:1695-1702. (Pubitemid 47010922)
33. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y: Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 2007;223:277-287. (Pubitemid 47362220)
34. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, Cowley H: Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000;28:772-780. (Pubitemid 30470827)
35. Hanefeld M: Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl. 2001;121:19-25. (Pubitemid 32916692)
36. Haskins JR, Rowse P, Rahbari R, de la Iglesia FA: Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 2001;75:425-438. (Pubitemid 32905560)
37. Blanquicett C, Roman J, Hart CM: Thiazolidinediones as anti-cancer agents. Cancer Ther 2008;6:25-34.
38. Masubuchi Y, Kano S, Horie T: Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006;222:233-239.
39. Yokoi T: Troglitazone. Handb Exp Pharmacol 2010;196:419-435.
40. Liao X, Wang Y, Wong CW: Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol 2010;161:771-781.
41. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820. (Pubitemid 34000785)
42. Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A: Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 2009;89:27-71.
43. McGuire DK, Inzucchi SE: New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation 2008;117:440-449.
44. Nissen SE: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573. (Pubitemid 351482795)
45. Ceolotto G, Gallo A, Papparella I, Franco L, Murphy E, Iori E, Pagnin E, Fadini GP, Albiero M, Semplicini A, Avogaro A: Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol 2007:27:2627-2633. (Pubitemid 350158915)
46. Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, Leverve X: Metformin inhibits mitochondrial permeability transition and cell death: A pharmacological in vitro study. Biochem J 2004;382:877-884. (Pubitemid 39312902)
47. Bogacka I, Xie H, Bray GA, Smith SR: Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005;54:1392-1399. (Pubitemid 40586669)
48. Da Silva Morais A, Lebrun V, Abarca-Quinones J, Brichard S, Hue L, Guigas B, Viollet B, Leclercq IA: Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation. J Hepatol 2009;50:489-500.
49. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T; LIDO Study Group: Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-453.
50. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, Leverve XM: The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 2006;38:33-42. (Pubitemid 44078517)
51. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X: Dimethyl-biguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223-228. (Pubitemid 30038975)
52. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, Tomas E: Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-181. (Pubitemid 44035323)